Table 1.
Therapeutic targets related to breast cancer stem cell pathways and platelet content
|
Breast cancer
|
Target/Pathway
|
Treatment Phase
|
Drug name
|
Ref.
|
| BC | CXCR4 | - | Plerixafor | [136] |
| BC | TGFß | - | Trabedersen | [137] |
| BC | DDL4/Notch | I | Demcizumab | [138] |
| BC, TNBC | Notch3 | I | AntiNotch3-ADC | [139] |
| BC | Wnt | I | Ipafricept | [140] |
| BC | PI3K | I | Alpelisib | [141] |
| TNBC | PI3K | I | Buparlisib | [142] |
| MBC | CXCR1 | Ib | Reparixin | [143] |
| BC | EpCAM | II | Adecatumumab | [144] |
| TNBC | Notch | II | Nirogacestat | [145] |
| MTNBC | JAK | II | Ruxolitinib | [146] |
| MBC | VEGF | III | Bevacizumab | [147] |
BC: Breast Cancer; TNBC: Triple-negative breast cancer; MBC: Metastatic breast cancer; MTNBC: Metastatic triple-negative breast cancer.